The first TUB-040 data come just after Tubulis raised €308m.
ApexOnco Front Page
Recent articles
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
A single but durable stable disease sends the microcap's stock up 730%.
MK-8294 starts phase 1, but its mechanism is anybody's guess.
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
A newly published cache of CRLs includes six novel oncology drugs.
Autogene cevumeran goes on hold in adjuvant bladder cancer.
The deal for ISB 2001 is worth $700m up front.
